The role of S6K1 in ER-positive breast cancer

Cell Cycle

Volumn 11, Issue 17, 2012, Pages 3159-3165

  Holz, Marina K ^a,b  

^a YESHIVA UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

17q23 amplicon; ER ; Estrogen; mTORC1; Rapamycin; S6K1

Indexed keywords

40S RIBOSOMAL S6 KINASE 1; AMINO ACID; ESTRADIOL; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; S6 KINASE; UNCLASSIFIED DRUG;

AMPLICON; APOPTOSIS; CANCER PROGNOSIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 17Q; ENERGY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; HUMAN; HYPOXIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84866290868     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21194     Document Type: Review

References (79)

1. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457-68; PMID:12408816; http://dx.doi.org/10.1016/S1097-2765(02)00636-6.
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(Suppl):7S-14S; PMID:12742462; http://dx.doi.org/10.1016/S0041-1345(03)00211-2.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7; PMID:12040186; http://dx.doi.org/10.1126/science.296.5573.1655.
4. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274:8347-50; PMID:10085060; http://dx.doi.org/10.1074/jbc.274.13.8347.
5. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29:32-8; PMID:14729330; http://dx.doi.org/10.1016/j.tibs.2003.11.007.
6. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15:702-13; PMID:15854902; http://dx.doi.org/10.1016/j.cub.2005.02.053.
7. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167:399-403; PMID:15533996; http://dx.doi.org/10.1083/jcb.200408161.
8. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121:179-93; PMID:15851026; http://dx.doi.org/10.1016/j.cell.2005.02.031.
9. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 2004; 101:13489-94; PMID:15342917; http://dx.doi.org/10.1073/pnas.0405659101.
10. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45; PMID:15314020; http://dx.doi.org/10.1101/gad.1212704.
11. Martin KA, Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 2002; 86:1-39; PMID:12374276; http://dx.doi.org/10.1016/S0065-230X(02)86001-8.
12. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011; 108:E1204-13; PMID:22065737; http://dx.doi.org/10.1073/pnas.1110195108.
13. Romanelli A, Dreisbach VC, Blenis J. Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem 2002; 277:40281-9; PMID:12183455; http://dx.doi.org/10.1074/jbc.M205168200.
14. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71; PMID:15094765; http://dx.doi.org/10. 1038/sj.onc.1207542.
15. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 1998; 17:6649-59; PMID:9822608; http://dx.doi.org/10.1093/ emboj/17.22.6649.
16. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123:569-80; PMID:16286006; http://dx.doi.org/10.1016/j.cell.2005.10.024.
17. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314:467-71; PMID:17053147; http://dx.doi.org/10.1126/science.1130276.
18. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009; 284:6361-9; PMID:19112174; http://dx.doi.org/ 10.1074/jbc. M807532200.
19. Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/ RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 2010; 584:124-8; PMID:19925796; http://dx.doi.org/10.1016/j.febslet.2009. 11.041.
20. Ma XM, Yoon SO, Richardson CJ, Jülich K, Blenis J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 2008; 133:303-13; PMID:18423201; http://dx.doi.org/10.1016/ j.cell.2008.02.031.
21. Jenö P, Ballou LM, Novak-Hofer I, Thomas G. Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci USA 1988; 85:406-10; PMID:3257566; http://dx.doi.org/10.1073/pnas.85.2.406.
22. Lane HA, Fernandez A, Lamb NJ, Thomas G. p70s6k function is essential for G1 progression. Nature 1993; 363:170-2; PMID:8483501; http://dx.doi.org/10. 1038/363170a0.
23. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24:200-16; PMID:14673156; http://dx.doi.org/10.1128/MCB.24.1.200-216.2004.
24. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/ MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64; PMID:21411864.
25. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497.
26. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29:4452-61; PMID:22010023; http://dx.doi.org/10.1200/JCO.2010.34.4879.
27. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992; 339:1-15; PMID:1345950.
28. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004; 9(Suppl 3):20-6; PMID:15163844; http://dx.doi.org/10.1634/theoncologist.9-suppl-3-20.
29. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9; PMID:22149876; http://dx.doi.org/10.1056/ NEJMoa1109653.
30. Miller WR, Larionov AA. Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 2012; 14:201; PMID:22277572; http://dx.doi.org/10.1186/bcr2931.
31. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29:4452-61; PMID:22010023; http://dx.doi.org/10.1200/JCO.2010.34.4879.
32. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J Biol Chem 2005; 280:33006-14; PMID:16076840; http://dx.doi.org/10.1074/jbc.M506758200.
33. Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 1999; 274:22296-302; PMID:10428798; http://dx.doi.org/10.1074/jbc.274.32.22296.
34. Thomas RS, Sarwar N, Phoenix F, Coombes RC, Ali S. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptoralpha activity. J Mol Endocrinol 2008; 40:173-84; PMID:18372406; http://dx.doi.org/10. 1677/JME-07-0165.
35. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002; 21:4921-31; PMID:12118371; http://dx.doi.org/10.1038/ sj.onc.1205420.
36. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 2005; 18:71-82; PMID:15808510; http://dx.doi.org/10.1016/j.molcel.2005.03.006.
37. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, et al. Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 2006; 66:10162-70; PMID:17047081; http://dx.doi.org/10.1158/0008-5472.CAN- 05-4111.
38. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol 2011; 25:516-28; PMID:21292829; http://dx.doi.org/10.1210/me.2010- 0373.
39. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001; 276:9817-24; PMID:11139588; http://dx.doi.org/10.1074/jbc.M010840200.
40. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008; 99:1992-2003; PMID:19016759.
41. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 1999; 19:1002-15; PMID:9891036.
42. Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA. Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology 2004; 145:2730-8; PMID:15033909; http://dx.doi.org/10.1210/en. 2003-1470.
43. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5:597-605; PMID:15193262; http://dx.doi.org/10.1016/j.ccr.2004.05.016.
44. Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, et al. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010; 29:2404-14; PMID:20101208; http://dx.doi.org/10.1038/onc.2009.520.
45. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120:2406-13; PMID:20530877; http://dx.doi.org/10.1172/JCI41680.
46. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007; 18:1323-8; PMID:17693645; http://dx.doi.org/10.1093/ annonc/mdm170.
47. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-28; PMID:16033851; http://dx.doi.org/10.1158/1078-0432.CCR-04-2402.
48. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011; 71:6773-84; PMID:21908557; http://dx.doi.org/10.1158/0008-5472.CAN-11-1295.
49. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, et al. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat 2011; 126:93-9; PMID:21184268; http://dx.doi.org/10.1007/s10549-010-1315-z.
50. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10:1013-23; PMID:14871980; http://dx.doi.org/10.1158/1078-0432.CCR-03- 0043.
51. Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003; 78:313-22; PMID:12755490; http://dx.doi.org/10.1023/A:1023081624133.
52. Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000; 92:1252-9; PMID:10922410; http://dx.doi. org/10.1093/jnci/92.15.1252.
53. van der Hage JA, van den Broek LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 2004; 90:1543-50; PMID:15083183; http://dx.doi.org/10.1038/sj.bjc.6601741.
54. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008; 110:477-83; PMID:17805960; http://dx.doi.org/10.1007/s10549-007-9746-x.
55. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res 2009; 69:3795-801; PMID:19336569; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4596.
56. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007; 12:104-7; PMID:17692802; http://dx.doi.org/10.1016/j. ccr.2007.07.014.
57. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 1999; 59:1408-11; PMID:10197603.
58. Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, et al. Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 2001; 98:5711-6; PMID:11331760; http://dx.doi.org/10.1073/pnas.091582298.
59. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD, et al. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res 2000; 60:5371-5; PMID:11034073.
60. Savelyeva L, Claas A, Matzner I, Schlag P, Hofmann W, Scherneck S, et al. Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers. Cancer Res 2001; 61:5179-85; PMID:11431357.
61. Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S, et al. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene 2012; PMID:22286763; http://dx.doi.org/10.1038/onc.2011. 657.
62. Cicatiello L, Scafoglio C, Altucci L, Cancemi M, Natoli G, Facchiano A, et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004; 32:719-75; PMID:15171711; http://dx.doi.org/10.1677/jme.0.0320719.
63. Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008; 4:188; PMID:18414489; http://dx.doi.org/10.1038/msb.2008.25.
64. Davis AM, Mao J, Naz B, Kohl JA, Rosenfeld CS. Comparative effects of estradiol, methyl-piperidinopyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus. J Mol Endocrinol 2008; 41:205-17; PMID:18632874; http://dx.doi.org/10.1677/JME-08-0029.
65. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, et al. Estradiolregulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 2009; 37:4850-61; PMID:19528081; http://dx.doi.org/10.1093/nar/gkp500.
66. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res 2009; 37:2584-95; PMID:19264808; http://dx.doi.org/10.1093/nar/gkp117.
67. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, et al. Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res 2011; 21:676-87; PMID:21467264; http://dx.doi.org/10.1101/gr.113225. 110.
68. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-58; PMID:11566616; http://dx.doi.org/10.1677/erc.0.0080249.
69. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-87; PMID:19332717; http://dx.doi.org/10.1200/JCO.2008.20.0766.
70. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, et al. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2012; PMID:22245973; http://dx.doi.org/10.1007/s10549-011-1910-7.
71. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10:8059-67; PMID:15585641; http://dx.doi.org/10.1158/1078-0432.CCR-04-0035.
72. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538-50; PMID:21730367.
73. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27:2630-7; PMID:19380449; http://dx.doi.org/10.1200/ JCO.2008.18.8391.
74. Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, et al. Gene expression profiling of response to mTOR inhibitor everolimus in preoperatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 2010; 122:419-28; PMID:20480226; http://dx.doi.org/10.1007/s10549-010-0928-6.
75. O'Regan R, Hawk NN. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 2011; 15:859-72; PMID:21476875; http://dx.doi.org/10.1517/14728222.2011.575362.
76. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009; 7:511-22; PMID:19372580; http: //dx.doi.org/10.1158/1541-7786. MCR-08-0107.
77. Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006; 6:92; PMID:16608533; http://dx.doi.org/10.1186/1471-2407-6-92.
78. Hynes NE, Boulay A. The mTOR pathway in breast cancer. J Mammary Gland Biol Neoplasia 2006; 11:53-61; PMID:16900391; http://dx.doi.org/10.1007/s10911- 006-9012-6.
79. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, et al. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008; 14:2673-80; PMID:18451231; http://dx.doi.org/10. 1158/1078-0432.CCR-07-1046.